Previous 10 | Next 10 |
LP352 Phase 1b/2a PACIFIC Study in participants with a range of developmental and epileptic encephalopathies (DEEs) ages 12-65 on track for topline data in second half 2023 Phase 1 open-label study to assess central nervous system (CNS) pharmacokinetics (PK) and pharmacodyna...
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard’s President & C...
Gainers: Axsome Therapeutics AXSM +31% . Summit Therapeutics SMMT +25% . Assure Holdings ( IONM ) +13% . Longboard Pharmaceuticals ( LBPH ) +10% . TransCode Therapeutics ( RNAZ ) +8% . Losers: Accelerate Diagnostics AXDX -27...
Longboard Pharmaceuticals press release ( NASDAQ: LBPH ): Q2 GAAP EPS of -$0.67 misses by $0.13 . Cash, cash equivalents and short-term investments were approximately $87.4 million. Cash position is expected to support operations into 2024 based on our current business...
LP352 Phase 1b/2a PACIFIC Study remains on track for completion in the second half of 2023; recently expanded the participant age range to 12-65 years old and added open-label extension study Initiated a Phase 1 open-label study to assess central nervous system (CNS) pharmacok...
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financia...
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard’s President & CE...
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its leadership team will participate i...
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will partici...
Longboard Pharmaceuticals press release (NASDAQ:LBPH): Q1 GAAP EPS of -$0.56. At March 31, 2022, Longboard’s cash, cash equivalents and short-term investments were approximately $96.1 million. Our cash position is expected to support operations into 2024 based on our current business p...
News, Short Squeeze, Breakout and More Instantly...
Longboard Pharmaceuticals Inc. Company Name:
LBPH Stock Symbol:
NASDAQ Market:
Longboard Pharmaceuticals Inc. Website:
Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT) Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-st...
2024-07-16 13:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 15:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...